Sex differences in the characteristics and survival of patients with non‐small‐cell lung cancer: A retrospective analytical study based on real‐world clinical data of the Korean population

Abstract

Purpose This study aimed to investigate the differences in characteristics, clinical stages, treatment modalities, and survival outcomes in patients with non‐small‐cell lung cancer (NSCLC) based on sex differences using Korean nationwide registry data. Methods We analyzed the data of 8650 patients diagnosed with NSCLC between 2014 and 2017, obtained from the Korean Association for Lung Cancer Registry (KALC‐R). The Cox proportional hazard model was used to define the differences in survival based on sex. Propensity score matching was used to adjust for differences between men and women. Results Of a total of 10 943 patients, 8650 (79.1%) were diagnosed with NSCLC, of whom 68.7% were men and 31.3% were women. For NSCLC, the median age was higher (69.0 vs. 67.0, p < 0.001) and the proportion of ever‐smokers (84.5% vs. 10.8%, p < 0.001) was higher in men. Adenocarcinoma (55.5% vs. 90.4%, p < 0.001) and stage I NSCLC (26.3% vs. 41.3%, p < 0.001) were more common in women. Survival was significantly lower in men with NSCLC (hazard ratio [HR] 1.493 [95% confidence interval, CI 1.238–1.800], p < 0.001) even after adjusting for meaningful clinical variables, and in the matched cohort (HR 1.339 [1.075–1.667], p = 0.009). Similarly, survival was significantly lower in men with stage IV adenocarcinoma after adjusting for other clinical variables (HR 1.493 [1.238–1.800], p < 0.001) and in the matched cohort (HR 1.339 [1.075–1.667]; p = 0.009). Conclusions Male patients with NSCLC had poorer prognosis, not only after variable adjustments for prognostic factors, but also in the matched cohort.

Usefulness of 18F-FDG PET/computed tomography metabolic parameters in predicting sarcopenia and prognosis of treatment-naive patients with non-small cell lung cancer

“…Other factors such as advanced stage and sex (male) were found predictive of survival as well. We found sex predictive of OS, in keeping with prior findings [23–26]. We did not find sex predictive of PFS, but literature contradictory to this finding remains scarce.…”

High Pretreatment DHEA Is Associated with Inferior Immunotherapy Response in Metastatic Non-Small Cell Lung Cancer

“…This theory remains speculative within the context of our study, as cortisol measurements were not included in our patient evaluations, In addition to DHEA, sex itself could be a prognostic factor instead of a predictive factor in clinical outcomes in NSCLC. Data from the Korean Association for Lung Cancer Registry showed that male patients with NSCLC had poorer prognoses compared to females after adjusting for clinical variables, and the difference was consistent across stages of diseases [35]. Another comprehensive analysis using Swedish national populationbased registries described the sex difference in NSCLC outcomes.…”

Analysis of the clinical characteristics of pembrolizumab-induced bullous pemphigoid

“…The present study, which included 47 patients, demonstrated pembrolizumab therapy could cause BP. Interestingly, studies have linked irAEs to higher rates of treatment success and improved survival following pembrolizumab therapy (56,57). Furthermore, it has been suggested that the occurrence of irCAEs may be a useful indicator for predicting improved tumor response and better survival among cancer patients receiving ICIs immunotherapy (57,58).…”

“…Interestingly, studies have linked irAEs to higher rates of treatment success and improved survival following pembrolizumab therapy (56,57). Furthermore, it has been suggested that the occurrence of irCAEs may be a useful indicator for predicting improved tumor response and better survival among cancer patients receiving ICIs immunotherapy (57,58). However, the effectiveness of irAEs as a predictor was reduced because irAEs occurr ed only afte r IC Is tre atm ent commen ce ment .…”